SG11202111031RA - Rituximab-resistant chimeric antigen receptors and uses thereof - Google Patents

Rituximab-resistant chimeric antigen receptors and uses thereof

Info

Publication number
SG11202111031RA
SG11202111031RA SG11202111031RA SG11202111031RA SG11202111031RA SG 11202111031R A SG11202111031R A SG 11202111031RA SG 11202111031R A SG11202111031R A SG 11202111031RA SG 11202111031R A SG11202111031R A SG 11202111031RA SG 11202111031R A SG11202111031R A SG 11202111031RA
Authority
SG
Singapore
Prior art keywords
rituximab
chimeric antigen
antigen receptors
resistant chimeric
resistant
Prior art date
Application number
SG11202111031RA
Inventor
Thomas Charles Pertel
Barbra Johnson Sasu
Mark W Leonard
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Publication of SG11202111031RA publication Critical patent/SG11202111031RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
SG11202111031RA 2019-04-26 2020-04-24 Rituximab-resistant chimeric antigen receptors and uses thereof SG11202111031RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962839455P 2019-04-26 2019-04-26
US202063005041P 2020-04-03 2020-04-03
PCT/US2020/029775 WO2020219848A1 (en) 2019-04-26 2020-04-24 Rituximab-resistant chimeric antigen receptors and uses thereof

Publications (1)

Publication Number Publication Date
SG11202111031RA true SG11202111031RA (en) 2021-11-29

Family

ID=70847489

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111031RA SG11202111031RA (en) 2019-04-26 2020-04-24 Rituximab-resistant chimeric antigen receptors and uses thereof

Country Status (18)

Country Link
US (1) US11896617B2 (en)
EP (2) EP3959235B1 (en)
JP (1) JP2022532996A (en)
KR (1) KR20220004076A (en)
CN (1) CN113728001A (en)
AU (1) AU2020263495A1 (en)
BR (1) BR112021021178A2 (en)
CA (1) CA3134308A1 (en)
CO (1) CO2021014121A2 (en)
DK (1) DK3959235T3 (en)
ES (1) ES2961314T3 (en)
FI (1) FI3959235T3 (en)
IL (1) IL287487A (en)
MX (1) MX2021012820A (en)
PE (1) PE20212369A1 (en)
SG (1) SG11202111031RA (en)
TW (1) TW202106704A (en)
WO (1) WO2020219848A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3203531A1 (en) 2020-12-30 2022-07-07 Simon Olivares Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5830462A (en) 1993-02-12 1998-11-03 President & Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US20030036654A1 (en) 1994-08-18 2003-02-20 Holt Dennis A. Synthetic multimerizing agents
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU4328801A (en) 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20040054699A (en) 2001-10-02 2004-06-25 엥스띠뛰 끌레이톤 드 라 러쉐르쉬 Methods and compositions relating to restricted expression lentiviral vectors and their applications
WO2007137300A2 (en) 2006-05-23 2007-11-29 Bellicum Pharmaceuticals, Inc. Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
WO2011146862A1 (en) 2010-05-21 2011-11-24 Bellicum Pharmaceuticals, Inc. Methods for inducing selective apoptosis
SG10201510092QA (en) 2010-12-09 2016-01-28 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012103279A2 (en) 2011-01-26 2012-08-02 Ariad Pharmaceuticals, Incorporated Methods and compositions for the synthesis of multimerizing agents
BR112013024395B1 (en) 2011-03-23 2021-10-26 Fred Hutchinson Cancer Research Center ADOPTIVE COMPOSITIONS OF CELL IMMUNOTHERAPY AND METHOD FOR MANUFACTURING SUCH COMPOSITION
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
WO2014184143A1 (en) 2013-05-13 2014-11-20 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
BR112014029417B1 (en) * 2012-05-25 2023-03-07 Cellectis EX VIVO METHOD FOR THE PREPARATION OF T CELLS FOR IMMUNOTHERAPY
HUE047487T2 (en) 2013-02-15 2020-04-28 Univ California Chimeric antigen receptor and methods of use thereof
CA2905352A1 (en) 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
CA2956667A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
CN114395530A (en) 2014-02-04 2022-04-26 凯德药业公司 Methods for producing autologous T cells for the treatment of B cell malignancies and other cancers and compositions thereof
AU2015218396A1 (en) 2014-02-14 2016-08-11 Bellicum Pharmaceuticals, Inc. Methods for activating T cells using an inducible chimeric polypeptide
AU2015312117A1 (en) * 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
RU2017129455A (en) 2015-01-26 2019-03-04 Селлектис DESIGNED IMMUNE CELLS WITH T-CELL RECEPTOR KNOCKED WITH CHIMERIC ANTIGENE RECEPTORS, BINDING WITH CD123, FOR TREATMENT OF RESIDUAL ACCIDENTS
GB201518792D0 (en) * 2015-10-23 2015-12-09 Univ Manchester Production of proteins
EP3390432B1 (en) 2015-12-18 2020-09-23 Ucl Business Ltd Treatment
EP3443001A4 (en) * 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Regulated biocircuit systems
GB201609597D0 (en) 2016-06-01 2016-07-13 Univ Sheffield Therapy
CA3055202A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Cd19 compositions and methods for immunotherapy
EP3784785A4 (en) 2018-04-23 2022-02-16 Duke University Downregulation of snca expression by targeted editing of dna-methylation
SG11202101996QA (en) * 2018-08-28 2021-03-30 Immunotech Biopharm Co Ltd Improved therapeutic t cell

Also Published As

Publication number Publication date
WO2020219848A1 (en) 2020-10-29
DK3959235T3 (en) 2023-10-16
EP4295851A2 (en) 2023-12-27
IL287487A (en) 2021-12-01
TW202106704A (en) 2021-02-16
KR20220004076A (en) 2022-01-11
US11896617B2 (en) 2024-02-13
EP4295851A3 (en) 2024-02-14
CO2021014121A2 (en) 2021-10-29
CN113728001A (en) 2021-11-30
MX2021012820A (en) 2021-11-25
ES2961314T3 (en) 2024-03-11
EP3959235B1 (en) 2023-07-26
US20200384026A1 (en) 2020-12-10
FI3959235T3 (en) 2023-09-27
AU2020263495A1 (en) 2021-10-28
PE20212369A1 (en) 2021-12-21
CA3134308A1 (en) 2020-10-29
EP3959235A1 (en) 2022-03-02
BR112021021178A2 (en) 2022-03-15
JP2022532996A (en) 2022-07-21

Similar Documents

Publication Publication Date Title
IL275619A (en) Enhanced chimeric antigen receptors and uses thereof
IL279367A (en) Bcma chimeric antigen receptors and uses thereof
IL277078A (en) Anti-cd33 chimeric antigen receptors and their uses
IL280029A (en) Ror-1 specific chimeric antigen receptors and uses thereof
EP3658163A4 (en) Enhanced chimeric antigen receptors and use thereof
IL279979A (en) Chimeric antigen receptors with bcma specificity and uses thereof
IL286038A (en) Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
EP3827025A4 (en) Gd2-based chimeric antigen receptor and application thereof
IL280033A (en) Uses of anti-bcma chimeric antigen receptors
ZA202005837B (en) Cd83-binding chimeric antigen receptors
IL279310A (en) Cd79a chimeric antigen receptors
IL286984A (en) Humanized anti-dll3 chimeric antigen receptors and uses thereof
ZA202008065B (en) Muc16 specific chimeric antigen receptors and uses thereof
IL275040A (en) T-cells comprising two different chimeric antigen receptors and uses thereof
EP3919515A4 (en) Chimeric antigen receptor and use thereof
IL285587A (en) Hypoxia-responsive chimeric antigen receptors
IL285909A (en) Anti-bcma chimeric antigen receptors
EP4013798A4 (en) Chimeric antigen receptors and uses thereof
IL286696A (en) Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof
SG11202103095RA (en) Anti-human vsig4 antibodies and uses thereof
IL287310A (en) Antibodies against 4g7-derived chimeric antigen receptors
EP4032978A4 (en) Cd19-targeted chimeric antigen receptor and use thereof
IL287487A (en) Rituximab-resistant chimeric antigen receptors and uses thereof
GB2585607B (en) Chimeric antigen receptor and application thereof
IL281129A (en) Methods and compositions comprising b7h3 chimeric antigen receptors